Chimeric glycoproteins and pseudotyped lentiviral vectors
US8338168B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 25, 2003 |
| Grant date | Dec 25, 2012 |
| Priority date | — |
| Expiry date | Sep 13, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides improved chimeric glycoproteins (GPs) and improved lentiviral vectors pseudotyped with those glycoproteins. Also provided are methods and compositions for making such glycoproteins and vectors, and improved methods of in vitro and in vivo transduction of cells with such vectors. Improved chimeric GPs encode the extracellular and transmembrane domains of GALV or RD114 GPs fused to the cytoplasmic tail of MLV-A GP. Vectors pseudotyped with these GAL V/TR and RD 114/TR GP chimeras have significantly higher titers than vectors coated with the parental GPs. Additionally, RD114/TR-pseudotyped vectors are efficiently concentrated and are resistant to inactivation induced by the complement of both human and macaque sera. RD114 GP-pseudotyped lentiviral vectors have particular utility for in vivo gene transfer applications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.